NEWS
For Upcoming Meetings click on EVENTS
Prostate Cancer Foundation's (PCF) latest "State of the Science" Report is Here!
The 30th Annual PCF Scientific Retreat was held October 26-28, 2023, in Carlsbad, CA. This yearly invited gathering of researchers represents the foremost scientific conference in the world on the biology and treatment of prostate cancer. PCF now offers a hybrid format in which interested observers may register to attend virtually. PCF recently published the latest "State of the Science" Report.
Download it for free!
The 30th Annual PCF Scientific Retreat was held October 26-28, 2023, in Carlsbad, CA. This yearly invited gathering of researchers represents the foremost scientific conference in the world on the biology and treatment of prostate cancer. PCF now offers a hybrid format in which interested observers may register to attend virtually. PCF recently published the latest "State of the Science" Report.
Download it for free!
2023 Recap: New Treatments in Prostate Cancer
From Dr. Mark Scholz, MD, Prostate Cancer Research Institute (PCRI), January, 2024
Dr. Mark Scholz gives a short video update on new treatment prostate cancer therapies introduced in 2023.
See the video
From Dr. Mark Scholz, MD, Prostate Cancer Research Institute (PCRI), January, 2024
Dr. Mark Scholz gives a short video update on new treatment prostate cancer therapies introduced in 2023.
See the video
Five (5) Common Prostate Cancer Myths
From Sperling Prostate Center, January 18, 2024
Today’s world of prostate cancer is a far cry from what it was in your dad’s day. New knowledge about the disease includes a better understanding of prostate anatomy, prostate cancer genomics, the behavior of cancer cells, and the role of lifestyle. However, some old beliefs still linger. It’s time to put these myths to rest…
Read the article
From Sperling Prostate Center, January 18, 2024
Today’s world of prostate cancer is a far cry from what it was in your dad’s day. New knowledge about the disease includes a better understanding of prostate anatomy, prostate cancer genomics, the behavior of cancer cells, and the role of lifestyle. However, some old beliefs still linger. It’s time to put these myths to rest…
Read the article
COVID Can Mimic Prostate Cancer Symptoms
From Medscape Monday, January 15, 2024
If a patient's prostate specific antigen (PSA) spikes 2 points in just 90 days, what is your first thought? This patient has a strong likelihood of aggressive prostate cancer, right? If that same patient also presents with severe, burning bone pain with no precipitating trauma to the area and rest and over-the-counter painkillers are not helping, you'd think, "check for metastases," right?
That patient was me in late January 2023.
Read the article
From Medscape Monday, January 15, 2024
If a patient's prostate specific antigen (PSA) spikes 2 points in just 90 days, what is your first thought? This patient has a strong likelihood of aggressive prostate cancer, right? If that same patient also presents with severe, burning bone pain with no precipitating trauma to the area and rest and over-the-counter painkillers are not helping, you'd think, "check for metastases," right?
That patient was me in late January 2023.
Read the article
Early Prostate Cancer? Don't Go It Alone, Take the Bag!
Offered From Zero Cancer.org
Developed for men with early-stage (localized) prostate cancer, this new Bag It Prostate Cancer Bag will arm you-and your partner-with helpful tools and reliable information. It will empower you to make decisions and self-advocate during your prostate cancer journey. The bag includes a guidebook for prostate cancer patients that is free if you use the code included in the flyer. Use the link below.
Read the flyer, use the code, and get your free bag
Offered From Zero Cancer.org
Developed for men with early-stage (localized) prostate cancer, this new Bag It Prostate Cancer Bag will arm you-and your partner-with helpful tools and reliable information. It will empower you to make decisions and self-advocate during your prostate cancer journey. The bag includes a guidebook for prostate cancer patients that is free if you use the code included in the flyer. Use the link below.
Read the flyer, use the code, and get your free bag
Video: Treating the Side Effects of Hormone Therapy
by Dr. Mark Scholz, Prostate Cancer Research Institute (PCRI)
Mark Scholz, MD is a medical oncologist who specializes exclusively in the management and treatment of prostate cancer patients. Here, he and PCRI's Alex give a survey of everything a prostate cancer patient should know before starting hormone therapy for prostate cancer. The side effects of hormone therapy and the intensity of those side effects vary from person to person; however, there are established strategies to prevent and mitigate them to the greatest extent possible.
Watch the Video
by Dr. Mark Scholz, Prostate Cancer Research Institute (PCRI)
Mark Scholz, MD is a medical oncologist who specializes exclusively in the management and treatment of prostate cancer patients. Here, he and PCRI's Alex give a survey of everything a prostate cancer patient should know before starting hormone therapy for prostate cancer. The side effects of hormone therapy and the intensity of those side effects vary from person to person; however, there are established strategies to prevent and mitigate them to the greatest extent possible.
Watch the Video
Prostate Cancer Foundation's Best Content of 2023
Across all of the articles, videos, guides, and webinars on PCF.org, some top contenders garnered the most eyeballs this year. Readers and viewers searched for information on an array of topics, from the basics of PSA and diagnosis, to treatment options, to managing side effects, to staying healthy. We hope you find some new and meaningful information, and are inspired to continue learning and sharing with family, friends, and your treatment team. Enjoy PCF’s Best Read Content of 2023.
All About Hormone Therapy. Hormone therapy is a mainstay of treatment for many patients with prostate cancer. It can extend lives….but can have a wide range of possible side effects. Watch the video
Gleason Score and Grade Group. One important component of staging your cancer is the grade of the cancer. While the stage of your cancer looks at where the cancer is present in your body (how it is behaving at the macro level), the grade describes what the actual cancer cells look like under a microscope (how they are behaving on a micro level). Read More
Nutrition Guidance for Patients on Hormone Therapy. Did you know that what you eat, how much you move, and other health practices can not only affect your fight against prostate cancer….but also lower your risk of heart disease? Patients taking hormone therapy are especially encouraged to adopt heart-healthy habits. The good news is that “what’s good for your heart is good for your prostate.”
Read More
Prostate Cancer Symptoms and Signs. Unfortunately, there usually aren’t any early warning signs for prostate cancer. The growing tumor does not push against anything to cause pain, so for many years the disease may be silent. That’s why screening for prostate cancer is such an important topic for all men and their families. Read More
When Your PSA is Rising After Treatment. You’ve been through treatment for prostate cancer. Months or years later, you get the news you hoped would never come: your PSA is rising. Learn about what the numbers mean, testing beyond PSA, and treatment options.
Watch the Video
The Prostate-Specific Antigen (PSA) Test. The PSA test is the leading method of screening for prostate cancer. PSA screening can help catch the disease at an early stage when treatment may be more effective and potentially have fewer side effects. Read More
Steve’s Story: Cutting-Edge Care Makes All the Difference. In the past year, Steve has gotten cutting-edge combination treatment for metastatic prostate cancer. Things are going so well that his doctor may recommend that he can try going off his medications. But the picture was not always so rosy. He’s had to empower himself with knowledge and be his own advocate more than once along his prostate cancer journey. Read More
Make Sure Your PSA is as Accurate as Possible. PSA fluctuates; that’s why it’s good to follow the general trend of the number over time, instead of just looking at one reading and saying with absolute confidence that a man definitely does or does not have prostate cancer. That said, if you’re getting a PSA test, let’s make sure it’s as accurate as possible. Read More
Sexual Health and Incontinence Changes in urinary and sexual function are two of the most common—and most feared—possible side effects of treatment for localized prostate cancer. Fortunately, there is room for much optimism: there are many excellent options to manage them. Watch the Video
The Prostate Gland The more you know about the prostate, its normal development and function, where it's located, and what it's attached to, the better you can understand how prostate cancer can develop and impact a patient's life over time. Read More
Across all of the articles, videos, guides, and webinars on PCF.org, some top contenders garnered the most eyeballs this year. Readers and viewers searched for information on an array of topics, from the basics of PSA and diagnosis, to treatment options, to managing side effects, to staying healthy. We hope you find some new and meaningful information, and are inspired to continue learning and sharing with family, friends, and your treatment team. Enjoy PCF’s Best Read Content of 2023.
All About Hormone Therapy. Hormone therapy is a mainstay of treatment for many patients with prostate cancer. It can extend lives….but can have a wide range of possible side effects. Watch the video
Gleason Score and Grade Group. One important component of staging your cancer is the grade of the cancer. While the stage of your cancer looks at where the cancer is present in your body (how it is behaving at the macro level), the grade describes what the actual cancer cells look like under a microscope (how they are behaving on a micro level). Read More
Nutrition Guidance for Patients on Hormone Therapy. Did you know that what you eat, how much you move, and other health practices can not only affect your fight against prostate cancer….but also lower your risk of heart disease? Patients taking hormone therapy are especially encouraged to adopt heart-healthy habits. The good news is that “what’s good for your heart is good for your prostate.”
Read More
Prostate Cancer Symptoms and Signs. Unfortunately, there usually aren’t any early warning signs for prostate cancer. The growing tumor does not push against anything to cause pain, so for many years the disease may be silent. That’s why screening for prostate cancer is such an important topic for all men and their families. Read More
When Your PSA is Rising After Treatment. You’ve been through treatment for prostate cancer. Months or years later, you get the news you hoped would never come: your PSA is rising. Learn about what the numbers mean, testing beyond PSA, and treatment options.
Watch the Video
The Prostate-Specific Antigen (PSA) Test. The PSA test is the leading method of screening for prostate cancer. PSA screening can help catch the disease at an early stage when treatment may be more effective and potentially have fewer side effects. Read More
Steve’s Story: Cutting-Edge Care Makes All the Difference. In the past year, Steve has gotten cutting-edge combination treatment for metastatic prostate cancer. Things are going so well that his doctor may recommend that he can try going off his medications. But the picture was not always so rosy. He’s had to empower himself with knowledge and be his own advocate more than once along his prostate cancer journey. Read More
Make Sure Your PSA is as Accurate as Possible. PSA fluctuates; that’s why it’s good to follow the general trend of the number over time, instead of just looking at one reading and saying with absolute confidence that a man definitely does or does not have prostate cancer. That said, if you’re getting a PSA test, let’s make sure it’s as accurate as possible. Read More
Sexual Health and Incontinence Changes in urinary and sexual function are two of the most common—and most feared—possible side effects of treatment for localized prostate cancer. Fortunately, there is room for much optimism: there are many excellent options to manage them. Watch the Video
The Prostate Gland The more you know about the prostate, its normal development and function, where it's located, and what it's attached to, the better you can understand how prostate cancer can develop and impact a patient's life over time. Read More
Advancements in Prostate Cancer Treatment and Diagnosis (Video)
With Alex Rolland, Prostate Cancer Foundation Canada, August, 2023
This video Advancements in Prostate Cancer Treatment and Diagnosis was presented at the August 2023 meeting of the Canadian Coast to Coast Prostate Support Group. This presentation is for people with Aggressive and Advanced Prostate Cancers. It is on the technical side and may be difficult to follow, but gives ideas that those affected can discuss with their medical professionals. See the video by clicking on the following link. Advancements in Prostate Cancer Treatment and Diagnosis
With Alex Rolland, Prostate Cancer Foundation Canada, August, 2023
This video Advancements in Prostate Cancer Treatment and Diagnosis was presented at the August 2023 meeting of the Canadian Coast to Coast Prostate Support Group. This presentation is for people with Aggressive and Advanced Prostate Cancers. It is on the technical side and may be difficult to follow, but gives ideas that those affected can discuss with their medical professionals. See the video by clicking on the following link. Advancements in Prostate Cancer Treatment and Diagnosis
Blood in Urine After Prostate Radiation Therapy
Sept 19, 2023
The Prostate Cancer Research Institute has posted a very informative 15 minute video talk about finding blood in urine after radiation therapy. Approximately 1 in 4 cases find blood in urine after a period of time. Most of the time it is not a crucial condition and self correcting.
Watch the video by clicking here
Sept 19, 2023
The Prostate Cancer Research Institute has posted a very informative 15 minute video talk about finding blood in urine after radiation therapy. Approximately 1 in 4 cases find blood in urine after a period of time. Most of the time it is not a crucial condition and self correcting.
Watch the video by clicking here
How Do I Know my Prostate Cancer Treatment Worked?
August 31, 2023
When it comes to prostate cancer treatment, there is no “silver bullet” that a) works for everyone and b) assures a cure. Even prostatectomy, in which the entire gland is removed, has recurrence rates of roughly 20%. Therefore, all treatments require lifelong monitoring. The question is, how soon should monitoring begin, and what method is best?
Keep reading as we explore the effectiveness of various monitoring methods including MRI-guided techniques for personalized follow-up care and peace of mind... Read the full article
August 31, 2023
When it comes to prostate cancer treatment, there is no “silver bullet” that a) works for everyone and b) assures a cure. Even prostatectomy, in which the entire gland is removed, has recurrence rates of roughly 20%. Therefore, all treatments require lifelong monitoring. The question is, how soon should monitoring begin, and what method is best?
Keep reading as we explore the effectiveness of various monitoring methods including MRI-guided techniques for personalized follow-up care and peace of mind... Read the full article
Shining a Light on Genomic Somatic Testing vs. Germline Genetic Testing: We Patients Need Help
By Howard Wolinsky., July 12, 2023
When it comes to tissue-based genomic or somatic testing, patients with low-risk to favorable intermediate-risk prostate cancer are largely in the dark. Likewise, DNA or germline testing—looking at our inherited genes—is also confusing. I see in support groups I attend that men generally are not clear about the differences between DNA testing of their own genes and somatic or genomic testing of their prostate lesions. Read the Article
By Howard Wolinsky., July 12, 2023
When it comes to tissue-based genomic or somatic testing, patients with low-risk to favorable intermediate-risk prostate cancer are largely in the dark. Likewise, DNA or germline testing—looking at our inherited genes—is also confusing. I see in support groups I attend that men generally are not clear about the differences between DNA testing of their own genes and somatic or genomic testing of their prostate lesions. Read the Article
High Volume PCa: Trying to Rise Above the Den
--by Jeffrey Coleman, June 24, 2023
From 2018 through 2020 I had rising PSA levels each year (3.7 / 4.6 / 4.9). In June of 2020, I decided to see a urologist. At that time, I was 60 years old. I chose to go to Johns Hopkins, a local “center of excellence” in Baltimore, Maryland, which is thirty minutes from my home. My PSA test there came up again as 4.9. There was nothing felt by the doctor on the DRE. He recommended an MRI followed up by a biopsy. The results of the mpMRI (3 Tesla / with and without contrast) showed a small lesion within the prostate designated as a PIRADS 3 (equivocal / may or may not be cancer). I had a transperineal biopsy in September 2020.
Read the Article
--by Jeffrey Coleman, June 24, 2023
From 2018 through 2020 I had rising PSA levels each year (3.7 / 4.6 / 4.9). In June of 2020, I decided to see a urologist. At that time, I was 60 years old. I chose to go to Johns Hopkins, a local “center of excellence” in Baltimore, Maryland, which is thirty minutes from my home. My PSA test there came up again as 4.9. There was nothing felt by the doctor on the DRE. He recommended an MRI followed up by a biopsy. The results of the mpMRI (3 Tesla / with and without contrast) showed a small lesion within the prostate designated as a PIRADS 3 (equivocal / may or may not be cancer). I had a transperineal biopsy in September 2020.
Read the Article
High PSA, Low Gleason Score: Therapist Talks About Active Surveillance and How to He Handles Emotional Distress.
--by Michael Jon Altman, May 6, 2023
I must have been around nine or 10 years old when mortality smacked me in the face. I was reading the New York Daily News, while eating breakfast. and came across an article about scientists predicting the Earth would be burning up in 180 million years--give or take--as its orbit grows ever closer to the sun.
Fast forward to a couple of years ago when my 14.4 PSA score made an even greater impact: more like a punch in the solar plexus. My primary-care physician took the liberty, unbeknownst to me, of ordering a PSA (prostate-specific antigen) blood level screening.
Read the Article
--by Michael Jon Altman, May 6, 2023
I must have been around nine or 10 years old when mortality smacked me in the face. I was reading the New York Daily News, while eating breakfast. and came across an article about scientists predicting the Earth would be burning up in 180 million years--give or take--as its orbit grows ever closer to the sun.
Fast forward to a couple of years ago when my 14.4 PSA score made an even greater impact: more like a punch in the solar plexus. My primary-care physician took the liberty, unbeknownst to me, of ordering a PSA (prostate-specific antigen) blood level screening.
Read the Article
Sex and Intimacy After Prostate Cancer
--by Truenorth by Movember, Feb 22, 2023
This website contains a number of sections on sex and intimacy for those who have had prostate cancer treatment. True North is a global prostate cancer program proudly funded by Movember. Movember is a leading charity changing the face of men’s health on a global scale. Read the information articles on sex after prostate cancer.
--by Truenorth by Movember, Feb 22, 2023
This website contains a number of sections on sex and intimacy for those who have had prostate cancer treatment. True North is a global prostate cancer program proudly funded by Movember. Movember is a leading charity changing the face of men’s health on a global scale. Read the information articles on sex after prostate cancer.
Noninvasive Test Can Detect Even Trace Elements of Prostate Cancer
--by Cedars-Sinai Medical Center, Phys.org News, Feb 2, 2023
Cedars-Sinai Cancer investigators have developed a new nanotechnology-based test that can detect and profile prostate cancers—even in microscopic amounts. Their work, published in the journal Nano Today, suggests that this "liquid biopsy" test could spare many patients unnecessary treatment-related side effects, directing them instead to effective therapies that could prolong their lives. Read the article
--by Cedars-Sinai Medical Center, Phys.org News, Feb 2, 2023
Cedars-Sinai Cancer investigators have developed a new nanotechnology-based test that can detect and profile prostate cancers—even in microscopic amounts. Their work, published in the journal Nano Today, suggests that this "liquid biopsy" test could spare many patients unnecessary treatment-related side effects, directing them instead to effective therapies that could prolong their lives. Read the article
MRI-Guided RT Reduced Acute Toxic Effects in Men With Localized Prostate Cancer
— Compared with CT guidance, MRI strategy led to better patient-reported urinary and bowel outcomes
by Mike Bassett, Staff Writer, MedPage Today January 18, 2023
Stereotactic body radiotherapy (SBRT) guided by MRI for localized prostate cancer resulted in fewer toxicities and an improvement in quality of life compared with CT guidance, according to the randomized phase III MIRAGE trial. Read the article
— Compared with CT guidance, MRI strategy led to better patient-reported urinary and bowel outcomes
by Mike Bassett, Staff Writer, MedPage Today January 18, 2023
Stereotactic body radiotherapy (SBRT) guided by MRI for localized prostate cancer resulted in fewer toxicities and an improvement in quality of life compared with CT guidance, according to the randomized phase III MIRAGE trial. Read the article
Intense Exercise May Reduce Cancer Spread By Dr. Gabe Mirkin
-- December 1, 2022, By Dr. Gabe Mirkin
A study from Israel found that intense exercise may help to prevent cancer from spreading, in humans and in mice, by using up body sugars so that less energy is available for the tumor cells to grow and spread (Cancer Res, Nov 15, 2022;82(22):4164–4178). Researchers selected 2,734 Israeli men and women, ages 25 to 64, who were non-smokers, took no medications, and did not have cancer or chronic lung, heart, metabolic (diabetes), or orthopedic diseases. Read more in the article.
-- December 1, 2022, By Dr. Gabe Mirkin
A study from Israel found that intense exercise may help to prevent cancer from spreading, in humans and in mice, by using up body sugars so that less energy is available for the tumor cells to grow and spread (Cancer Res, Nov 15, 2022;82(22):4164–4178). Researchers selected 2,734 Israeli men and women, ages 25 to 64, who were non-smokers, took no medications, and did not have cancer or chronic lung, heart, metabolic (diabetes), or orthopedic diseases. Read more in the article.
Metastasis-Directed Therapy May Delay ADT in Advanced Prostate Cancer
— Surgery or radiation delayed initiation of systemic therapy by 18 months (article from MedPage Today)
by Charles Bankhead, Senior Editor, MedPage Today November 29, 2022
Metastasis-directed therapy (MDT) in selected patients with recurrent oligometastatic prostate cancer led to PSA responses in a majority of patients and delayed initiation of hormonal therapy by 18 months, a retrospective study showed. Read more in the article.
— Surgery or radiation delayed initiation of systemic therapy by 18 months (article from MedPage Today)
by Charles Bankhead, Senior Editor, MedPage Today November 29, 2022
Metastasis-directed therapy (MDT) in selected patients with recurrent oligometastatic prostate cancer led to PSA responses in a majority of patients and delayed initiation of hormonal therapy by 18 months, a retrospective study showed. Read more in the article.
Shorter Course of Radiation Therapy Proves Mettle in High-Risk Prostate Cancer
— Hypofractionation matches standard RT for survival and toxicity in a third less time
by Charles Bankhead, Senior Editor, MedPage Today October 25, 2022
SAN ANTONIO -- A shortened radiation therapy (RT) protocol for high-risk prostate cancer led to similar outcomes with no increase in toxicity compared with the standard treatment schedule, a randomized trial showed.
Overall survival (OS) at 7 years was 82%, with no difference between standard RT and hypofractionation that reduced treatment duration from 8 to 5 weeks. Prostate cancer-specific mortality (PCSM), biochemical failure-free survival (BFFS), and distant metastasis-free survival (DMFS) were all similar between treatment arms. Read more in the article
— Hypofractionation matches standard RT for survival and toxicity in a third less time
by Charles Bankhead, Senior Editor, MedPage Today October 25, 2022
SAN ANTONIO -- A shortened radiation therapy (RT) protocol for high-risk prostate cancer led to similar outcomes with no increase in toxicity compared with the standard treatment schedule, a randomized trial showed.
Overall survival (OS) at 7 years was 82%, with no difference between standard RT and hypofractionation that reduced treatment duration from 8 to 5 weeks. Prostate cancer-specific mortality (PCSM), biochemical failure-free survival (BFFS), and distant metastasis-free survival (DMFS) were all similar between treatment arms. Read more in the article
What to Do if Prostate Cancer Comes Back after Radiation
--Published by Sperling Prostate Center, Oct 13, 2022
No one wants to hear that their prostate cancer has returned after an initial whole-gland treatment like surgery or radiation. Sadly, at this time there is no treatment that offers a guaranteed cure. While 5-year survival rates for localized prostate cancer approach 100%, over the longer term as many as 20-40% of patients will experience recurrence.
So what can you do if prostate cancer comes back after radiation? We explore the options in the article. Read the article
Note: This article is for informational purposes only and does not include an endorsement for the Sperling Prostate Center.
--Published by Sperling Prostate Center, Oct 13, 2022
No one wants to hear that their prostate cancer has returned after an initial whole-gland treatment like surgery or radiation. Sadly, at this time there is no treatment that offers a guaranteed cure. While 5-year survival rates for localized prostate cancer approach 100%, over the longer term as many as 20-40% of patients will experience recurrence.
So what can you do if prostate cancer comes back after radiation? We explore the options in the article. Read the article
Note: This article is for informational purposes only and does not include an endorsement for the Sperling Prostate Center.
Prostate Cancer Treatment May Rewire Tumor Engine, Potentially Increasing Aggressiveness
--Published in Genetic Engineering & Biotechnology News
A study by researchers at the University of Michigan Rogel Cancer Center suggests that androgen receptor (AR) inhibitor drugs, such as enzalutamide (enza) can fundamentally rewire and reshape how prostate tumors function, and in certain cases even make them more aggressive. The team carried out gene expression profiling of biopsies of metastatic castration-resistant prostate cancer (CRPC) from men prior to treatment using enza, and also at progression. Their analyses indicated evidence of lineage plasticity, and also identified a gene signature, which they have yet to validate, associated with a risk of therapy-induced lineage plasticity and poor patient survival.
Read the full article
--Published in Genetic Engineering & Biotechnology News
A study by researchers at the University of Michigan Rogel Cancer Center suggests that androgen receptor (AR) inhibitor drugs, such as enzalutamide (enza) can fundamentally rewire and reshape how prostate tumors function, and in certain cases even make them more aggressive. The team carried out gene expression profiling of biopsies of metastatic castration-resistant prostate cancer (CRPC) from men prior to treatment using enza, and also at progression. Their analyses indicated evidence of lineage plasticity, and also identified a gene signature, which they have yet to validate, associated with a risk of therapy-induced lineage plasticity and poor patient survival.
Read the full article
Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases
— However, no benefit seen with short-term hormone therapy versus radiotherapy alone
by Mike Bassett, Staff Writer, MedPage Today September 13, 2022
In men undergoing radiotherapy after radical prostatectomy, 2 years of androgen deprivation therapy (ADT) improved outcomes when compared with a shorter course of ADT, according to results from the RADICALS-HD trial.
Read the full article
— However, no benefit seen with short-term hormone therapy versus radiotherapy alone
by Mike Bassett, Staff Writer, MedPage Today September 13, 2022
In men undergoing radiotherapy after radical prostatectomy, 2 years of androgen deprivation therapy (ADT) improved outcomes when compared with a shorter course of ADT, according to results from the RADICALS-HD trial.
Read the full article
Dr. Gabe Mirkin's Talk on Nutrition: Wednesday, Aug 3, 2022
Dr. Gabe Mirkin talked about nutrition and you can view his presentation by clicking on the following link:
Dr. Mirkin's Presentation Slides from his talk of August 3 2022
Dr. Gabe Mirkin talked about nutrition and you can view his presentation by clicking on the following link:
Dr. Mirkin's Presentation Slides from his talk of August 3 2022
ENACT Study Shows 'enza' Significantly Slows Progression of Low-risk Prostate Cancer By Howard Wolinsky
Is there a pill for low-risk prostate cancer? Maybe. But do we need it?
A study published June 16 in JAMA Oncology has shown that an anti-cancer medication, enzalutamide (Xtandi), can slow progression in a significant number of patients with low-risk (Gleason 3+3=6) and favorable intermediate risk (Gleason 3+4=7) prostate cancers who otherwise qualified for active surveillance (AS). Click here to read the study
Is there a pill for low-risk prostate cancer? Maybe. But do we need it?
A study published June 16 in JAMA Oncology has shown that an anti-cancer medication, enzalutamide (Xtandi), can slow progression in a significant number of patients with low-risk (Gleason 3+3=6) and favorable intermediate risk (Gleason 3+4=7) prostate cancers who otherwise qualified for active surveillance (AS). Click here to read the study
Just How Effective Is PSA Screening? by Mike Bassett, Staff Writer, MedPage Today May 18, 2022
— Study finds test has better benefit/harm trade-off than originally thought
NEW ORLEANS -- Prostate cancer screening with prostate-specific antigen (PSA) blood testing appears to have a more favorable benefit-to-harm trade-off than originally estimated, particularly among Black men, according to research presented here. Read full article
— Study finds test has better benefit/harm trade-off than originally thought
NEW ORLEANS -- Prostate cancer screening with prostate-specific antigen (PSA) blood testing appears to have a more favorable benefit-to-harm trade-off than originally estimated, particularly among Black men, according to research presented here. Read full article
Interest Grows for Focal Therapy in Treating Prostate Cancer
The following article is copied from the February newsletter of a prostate cancer support group called "BOB". Most of the members of this support group have undergone Proton Therapy Radiation. However, the group is interested in all aspects of prostate cancer. I present this here because our next speaker in June of 2022 is a urologist who performs focal therapy.
According to a recent article in the Urology Times Journal, “Forty percent of patients have treatment regret after being treated for prostate cancer because they feel like their quality of life was affected so much that the treatment was not worth it.” The article points out that the development and implementation of focal therapy for prostate cancer has the potential to significantly mitigate this problem.
Types of Focal Therapy There are many types of focal therapies including focal cryotherapy, high-intensity focused ultrasound (HIFU), focal laser ablation (FLA), focal cryotherapy and focal proton therapy, to name a few. A question we’re often asked by newly diagnosed patients is, “Focal therapy is used for treating other cancers, why not prostate cancer?”
The Appeal in Using Focal Therapy for Prostate Cancer
The interest in focal therapy for prostate cancer is motivated by several factors: 1) If focal therapy can destroy lesions within the prostate, then perhaps whole gland treatment isn’t necessary; 2) Focal therapy is typically short duration therapy, often one treatment in an outpatient setting; 3) If the whole gland isn’t treated, then the likelihood of side effects like impotence and incontinence are minimized or eliminated; 4) If there is a recurrence after the initial treatment, follow-up focal treatment should be possible, and finally; 5) A single, outpatient focal treatment would cost substantially less than hospital-based whole-gland treatment, making it more attractive to medical insurers to reimburse.
An Argument Against Using Focal Therapy for Prostate Cancer
A primary argument against focal prostate cancer therapy in the past has been the fact that imaging technology hadn’t developed to the point where it could find all the cancer/lesions in the prostate, and therefore, treating one or two lesions could easily leave cancer behind untreated. Whole gland treatment, therefore, can attack and destroy all the cancer in the prostate leaving doctor and patient confident in the outcome.
Change is Coming
While focal therapy is still considered investigational and there’s minimal long-term data supporting it, it’s an area of extreme interest by both patients and the medical community.
One of the most important enabling technological developments in recent years has been advances in multi-parametric MRI imaging technology, which we’ve covered quite extensively in past BOB Tales as well as in Bob’s new book. This new imaging, when combined with image-guided biopsies such as fusion-guided biopsy, can give doctors a much better picture of cancer activity within the prostate and a more clearly defined target for the biopsy needle. As a result of these developments, more is known about the extent and location of cancerous lesions and doctors have more confidence in cancer staging.
Researchers believe that more than 90 percent of patients could be served well with focal therapy. But there are many hurdles to overcome.
Widespread use of focal therapy for treating prostate cancer isn’t right around the corner, but researchers believe we’re on the right track and the goal will be reached in the not-too-distant future.
There’s an organization called The Focal Therapy Society whose mission is to advance and position minimally invasive treatments and image-targeted cancer treatment in a safe and effective gland-preserving manner to extend and maintain quality of life. Let’s hope they’re successful in achieving their objectives.
The following article is copied from the February newsletter of a prostate cancer support group called "BOB". Most of the members of this support group have undergone Proton Therapy Radiation. However, the group is interested in all aspects of prostate cancer. I present this here because our next speaker in June of 2022 is a urologist who performs focal therapy.
According to a recent article in the Urology Times Journal, “Forty percent of patients have treatment regret after being treated for prostate cancer because they feel like their quality of life was affected so much that the treatment was not worth it.” The article points out that the development and implementation of focal therapy for prostate cancer has the potential to significantly mitigate this problem.
Types of Focal Therapy There are many types of focal therapies including focal cryotherapy, high-intensity focused ultrasound (HIFU), focal laser ablation (FLA), focal cryotherapy and focal proton therapy, to name a few. A question we’re often asked by newly diagnosed patients is, “Focal therapy is used for treating other cancers, why not prostate cancer?”
The Appeal in Using Focal Therapy for Prostate Cancer
The interest in focal therapy for prostate cancer is motivated by several factors: 1) If focal therapy can destroy lesions within the prostate, then perhaps whole gland treatment isn’t necessary; 2) Focal therapy is typically short duration therapy, often one treatment in an outpatient setting; 3) If the whole gland isn’t treated, then the likelihood of side effects like impotence and incontinence are minimized or eliminated; 4) If there is a recurrence after the initial treatment, follow-up focal treatment should be possible, and finally; 5) A single, outpatient focal treatment would cost substantially less than hospital-based whole-gland treatment, making it more attractive to medical insurers to reimburse.
An Argument Against Using Focal Therapy for Prostate Cancer
A primary argument against focal prostate cancer therapy in the past has been the fact that imaging technology hadn’t developed to the point where it could find all the cancer/lesions in the prostate, and therefore, treating one or two lesions could easily leave cancer behind untreated. Whole gland treatment, therefore, can attack and destroy all the cancer in the prostate leaving doctor and patient confident in the outcome.
Change is Coming
While focal therapy is still considered investigational and there’s minimal long-term data supporting it, it’s an area of extreme interest by both patients and the medical community.
One of the most important enabling technological developments in recent years has been advances in multi-parametric MRI imaging technology, which we’ve covered quite extensively in past BOB Tales as well as in Bob’s new book. This new imaging, when combined with image-guided biopsies such as fusion-guided biopsy, can give doctors a much better picture of cancer activity within the prostate and a more clearly defined target for the biopsy needle. As a result of these developments, more is known about the extent and location of cancerous lesions and doctors have more confidence in cancer staging.
Researchers believe that more than 90 percent of patients could be served well with focal therapy. But there are many hurdles to overcome.
Widespread use of focal therapy for treating prostate cancer isn’t right around the corner, but researchers believe we’re on the right track and the goal will be reached in the not-too-distant future.
There’s an organization called The Focal Therapy Society whose mission is to advance and position minimally invasive treatments and image-targeted cancer treatment in a safe and effective gland-preserving manner to extend and maintain quality of life. Let’s hope they’re successful in achieving their objectives.
Genetic Score Shows Promise for Honing PSA Precision
— Fewer unnecessary biopsies projected with use of genetics-adjusted values
by Charles Bankhead, Senior Editor, MedPage Today April 12, 2022
NEW ORLEANS -- Adjusting prostate-specific antigen (PSA) levels for normal genetic variations showed potential for making PSA testing more useful, including reducing unnecessary prostate biopsies, a large genome-wide association study (GWAS) suggested. A "polygenic score" (PGS) that accounted for noncancerous variations in PSA values explained 7.3%-8.8% of the variation in baseline PSA values in two large prostate cancer prevention studies. Correcting PSA values for noncancerous variations would have led to almost 20% fewer negative biopsies in men without cancer and 15.7% fewer biopsies in men with low-risk disease. To read the entire article, click here
— Fewer unnecessary biopsies projected with use of genetics-adjusted values
by Charles Bankhead, Senior Editor, MedPage Today April 12, 2022
NEW ORLEANS -- Adjusting prostate-specific antigen (PSA) levels for normal genetic variations showed potential for making PSA testing more useful, including reducing unnecessary prostate biopsies, a large genome-wide association study (GWAS) suggested. A "polygenic score" (PGS) that accounted for noncancerous variations in PSA values explained 7.3%-8.8% of the variation in baseline PSA values in two large prostate cancer prevention studies. Correcting PSA values for noncancerous variations would have led to almost 20% fewer negative biopsies in men without cancer and 15.7% fewer biopsies in men with low-risk disease. To read the entire article, click here
THREE Different Doctors in Prostate Cancer - How Do I Know Which One to See?
Have you ever wondered about the differences between urologists, medical oncologists and radiation oncologists. Check out this video that explains the differences and how each can help you. Click here learn about THREE Different Doctors in Prostate Cancer
Have you ever wondered about the differences between urologists, medical oncologists and radiation oncologists. Check out this video that explains the differences and how each can help you. Click here learn about THREE Different Doctors in Prostate Cancer
Best Way to Recover Urinary Continence After Prostatectomy?
by Mike Bassett, Staff Writer, MedPage Today September 13, 2021
— Nerve-sparing prostatectomy, not rehab or duloxetine, is the most important factor
-- Pelvic floor muscle training (PFMT) and the use of duloxetine (Cymbalta) may not be the best options for recovering urinary continence after robotic-assisted radical prostatectomy, according to the randomized IMPROVE trial.
Click here to read the article
Which Prostate Biopsy Is Best: Transrectal or Transperineal?
by Howard Wolinsky, Contributing Writer, MedPage Today September 13, 2021
— Advocates for one may face uphill battle, debate at AUA meeting suggests
-- If the Crossfire debate at the American Urological Association (AUA) virtual annual meeting is any indication, advocates for transperineal (TP) biopsies face an uphill battle in persuading U.S. urologists to adopt the practice. The issue of transrectal versus TP biopsies has been simmering worldwide in recent years. The European Association of Urology not long ago adopted a guideline that designated TP as the preferred biopsy method. Transrectal biopsies have already lost favor in Norway, much of the U.K., Australia, and other countries, as urologists hope to prevent infections and potentially deadly biopsies and find more prostate cancers.
Click here to read the article
by Mike Bassett, Staff Writer, MedPage Today September 13, 2021
— Nerve-sparing prostatectomy, not rehab or duloxetine, is the most important factor
-- Pelvic floor muscle training (PFMT) and the use of duloxetine (Cymbalta) may not be the best options for recovering urinary continence after robotic-assisted radical prostatectomy, according to the randomized IMPROVE trial.
Click here to read the article
Which Prostate Biopsy Is Best: Transrectal or Transperineal?
by Howard Wolinsky, Contributing Writer, MedPage Today September 13, 2021
— Advocates for one may face uphill battle, debate at AUA meeting suggests
-- If the Crossfire debate at the American Urological Association (AUA) virtual annual meeting is any indication, advocates for transperineal (TP) biopsies face an uphill battle in persuading U.S. urologists to adopt the practice. The issue of transrectal versus TP biopsies has been simmering worldwide in recent years. The European Association of Urology not long ago adopted a guideline that designated TP as the preferred biopsy method. Transrectal biopsies have already lost favor in Norway, much of the U.K., Australia, and other countries, as urologists hope to prevent infections and potentially deadly biopsies and find more prostate cancers.
Click here to read the article
How Do You Work Those Doctors' Appointments?
No matter what you research or learn about your cancer, you need to be able to talk it over in your DOCTORS' APPOINTMENTS. Whether those appointments are 15 min long, or 2 hours long - this is the time when you make your research count, and your decisions happen. As we all know, the medical system can be complicated or exhausting. Patients and caregivers and doctors can all feel overwhelmed at times. How do you keep the cancer patient first, and have the kind of conversations you need?
With Joel's 20 years of doctors' appointments for his 5 different cancers, and with Jan's 13 years of doctors' appointments for her husband's metastatic prostate cancer (PSA over 7,000), they have much to share.
Listen as JOEL (interviewed by Jan) tells his 3 stories which include these
Click HERE for JOEL'S Video/Stories
Take-home Lessons:
Listen as JAN (interviewed by Joel) tells her 3 stories.
Click HERE for JAN'S Video/Stories
Take-home Lessons:
No matter what you research or learn about your cancer, you need to be able to talk it over in your DOCTORS' APPOINTMENTS. Whether those appointments are 15 min long, or 2 hours long - this is the time when you make your research count, and your decisions happen. As we all know, the medical system can be complicated or exhausting. Patients and caregivers and doctors can all feel overwhelmed at times. How do you keep the cancer patient first, and have the kind of conversations you need?
With Joel's 20 years of doctors' appointments for his 5 different cancers, and with Jan's 13 years of doctors' appointments for her husband's metastatic prostate cancer (PSA over 7,000), they have much to share.
Listen as JOEL (interviewed by Jan) tells his 3 stories which include these
Click HERE for JOEL'S Video/Stories
Take-home Lessons:
- Bring Someone to Your Appointment
- Listen to Your Advocate
- Pick Your Battles
- Write Your Questions Down
- Trust Your Instincts
- Listen to Your Body
- last but not least - The NOWAK SHUFFLE..
Listen as JAN (interviewed by Joel) tells her 3 stories.
Click HERE for JAN'S Video/Stories
Take-home Lessons:
- "Medical Records Speak"
- Better Questions will get you Better Answers
- Shared Decision Making
- Keeping the Cancer Patient First in the Appointment
- "Run Ahead and Wait" (for your husband)
- No Doctors are Perfect - The Relationship is Everything
- Changing Doctors & the "3-Strike Rule"
- What's the Difference between a Urologist and a Medical Oncologist?
- Talk to the NURSE about Side Effects
Getting a Second Opinion on Your Pathology Report
Most people believe that pathology reports are always correct, accurate and that what the report says is carved in stone. This is not true.
Pathology reports are subjective. They are not objective. Pathology reports are the opinion and interpretation of the individual pathologist viewing the tissue samples. It is not uncommon that two different pathologists looking at the same slide come to a different interpretation and opinion about what is in their microscope! Good pathology readings require experience and a high level of expertise. Some specialists have more expertise and more experience than others.
Read more in the Cancer ABCs Article
Most people believe that pathology reports are always correct, accurate and that what the report says is carved in stone. This is not true.
Pathology reports are subjective. They are not objective. Pathology reports are the opinion and interpretation of the individual pathologist viewing the tissue samples. It is not uncommon that two different pathologists looking at the same slide come to a different interpretation and opinion about what is in their microscope! Good pathology readings require experience and a high level of expertise. Some specialists have more expertise and more experience than others.
Read more in the Cancer ABCs Article
Disclaimer: The Villages Prostate Group does not recommend or endorse the speakers, publications or descriptions of publications. They are simply provided as additional resources for your information.